Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: L01XE

Balimek(binimetinib)

Melanoma

Marketing Authorisation Holder: Pierre Fabre Médicament

INN: binimetinib

Indication

Treatment of unresectable or metastatic melanoma. Treatment of unresectable melanoma, with NRA Q61 mutation.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Balimek — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.